UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
ZVSA holding history
ZyVersa Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ZVSA overviewAll 13F holders of ZVSAFull Q2 2026 holdings
- Shares (Q3 2025)
- 0
- Sold out in Q3 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 8
- Since Q1 2023
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q3 2025 | 0 | $0 | 0.0% | −39,280−100.0% | Sold out | Holders |
| Q2 2025 | 39,280 | $26.6K | <0.1% | +10,953+38.7% | Added | Holders |
| Q1 2025 | 28,327 | $17.8K | <0.1% | +24,140+576.5% | Added | Holders |
| Q4 2024 | 4,187 | $4.44K | <0.1% | +3,754+867.0% | Added | Holders |
| Q3 2024 | 433 | $1.04K | <0.1% | +433 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −19,909−100.0% | Sold out | Holders |
| Q1 2024 | 19,909 | $14.9K | <0.1% | +16,635+508.1% | Added | Holders |
| Q4 2023 | 3,274 | $2.95K | <0.1% | +3,167+2,959.8% | Added | Holders |
| Q3 2023 | 107 | $14 | <0.1% | +107 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −3,282−100.0% | Sold out | Holders |
| Q1 2023 | 3,282 | $6.33K | <0.1% | +3,282 | New | Holders |